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INTRODUCTION
Sex hormone-binding globulin (SHBG) is a serum glycopro-
tein produced predominantly in hepatocyts.1,2 It controls the 
transport of sex steroid hormones in the blood circulation to 
their target tissues.1,3 Many previous studies have revealed that 
low levels of serum SHBG are associated with metabolic syn-
drome, type II diabetes, and cardiovascular disease.4,5 Nonal-
coholic fatty liver disease (NAFLD) grade is also known to be 
inversely related to serum SHBG levels:6,7 as the grade of he-
patic steatosis increases, serum SHBG level decreases.2,7 He-
patocytes are the primary sites of SHBG synthesis, and there-
fore the synthesis of SHBG could be associated with liver 
function.1 Various studies have investigated the relationship 
between SHBG and biomarkers of liver function.8 However, 
despite several epidemiological studies, it is still controversial 
as to whether serum alanine aminotransferase (ATL) is asso-
ciated with SBHG. Flechtner-Mors, et al.2 found no relation-
ship between ALT and SHBG, while Ayala, et al.9 found that 
SHBG and ALT were inversely related with each other.1 Where-
as ALT is known to reflect hepatocellular injury or death, it is 
still unclear whether ALT, a liver function marker, modulates 
the relationship between SHBG and hepatic steatosis.10 Fur-
thermore, ALT is a predictive marker of insulin resistance11,12 
and several studies have suggested that hyperinsulinemia is 
associated with decreased expression of SHBG.13 
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This study aimed to investigate the association between 
SHBG and hepatocyte damage represented by ALT among Ko-
rean male patients with hepatic steatosis, enrolled in a health 
examination program.
MATERIALS AND METHODS
Study population
This retrospective study included 2837 men and women aged 
>19 years old who visited the Health Promotion Center of Gang-
nam Severance Hospital, Yonsei University College of Medi-
cine in Seoul, Korea. Subjects underwent routine health exami-
nation between January 2007 and July 2010. Of them, all female 
1118 subjects were excluded because most female subjects 
did not undergo tests for serum SHBG level. Also, an additional 
478 male subjects were excluded because of missing values. 
Subjects who were positive for hepatitis B surface antigen or 
hepatitis C antibody were also excluded. In addition, we ex-
cluded 143 subjects with a history of hepatocellular carcino-
ma and 155 subjects with alcohol consumption ≥140 g/week. 
Ultimately, a total of 922 men were included in this study.
Measurements
Examinations were performed by medical staff according to a 
standard protocol. Demographic, anthropometric, and labo-
ratory data were gathered for each participant. The participants 
were asked whether they were undergoing or had recently un-
dergone treatment for any disease. If the patient was under 
treatment, they were questioned for the date of diagnosis and 
a list of current medications. Trained staff reviewed the com-
pleted questionnaires and entered responses into the data-
base. Participants were classified as non-smokers, ex-smokers 
or current smokers. Subjects were categorized by alcohol in-
take as a heavy drinker (alcohol ingestion ≥140 g/week) or light 
drinker (alcohol ingestion <140 g/week). Body weight and 
height were measured in light indoor clothing and no shoes to 
the nearest 0.1 kg and 0.1 cm, respectively. Body mass index 
(BMI) was calculated as the ratio of weight (kg)/height (m2). 
Blood pressure measurement was obtained with the partici-
pant in the sitting position, after 5 min of rest using an auto-
mated device (TM-2665P, A&D Co., LTD., Tokyo, Japan).
The diagnosis of a fatty liver was based on abdominal ultra-
sonography with a 3.5-MHz transducer (HDI 5000, Philips, 
Bothell, WA, USA).14 Ultrasonography was performed by an 
experienced radiologist. Participants were diagnosed with fat-
ty liver if at least two of the following three findings were pres-
ent: increased liver echogenicity, deep attenuation, and vas-
cular blurring.
Venous blood sampling was performed after a fasting peri-
od of 12 h. White blood cell (WBC) counts were quantified by 
an automated blood cell counter (ADVIA 120, Bayer, Tarrytown, 
NY, USA). Fasting plasma glucose, total cholesterol, high den-
sity lipoprotein (HDL) cholesterol, triglycerides (TGs), and ALT 
were measured using a Hitachi7600-110 chemistry autoana-
lyzer (Hitachi, Tokyo, Japan). T3, free T4, and SHBG were mea-
sured via electrochemiluminescent methods using Modular 
E170 (Roche Diagnostics, Mannheim, Germany).
Statistical analysis
The distribution of SHBG was markedly skewed and log-trans-
formed in the analyses where normality was required. ALT el-
evation was defined as ALT ≥40 U/L.15,16 We divided the study 
participants into tertiles of SHBG levels with cut-points of 28.60 
and 48.90 nmol/L, and defined the lowest tertile of SHBG as 
low SHBG.17
Multivariable logistic regression was used to assess the as-
sociation of ALT elevation with risk of low SHBG. We adjusted 
for age, BMI, systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), WBC, glucose, T3, total cholesterol, HDL, and TG. 
To investigate the interrelationships among hepatic steatosis, 
elevated ALT levels, and risk of low SHBG, we divided our par-
ticipants into the following three groups: a reference group of 
participants who had no hepatic steatosis and no ALT eleva-
tion, the hepatic steatosis group without ALT elevation, and the 
hepatic steatosis with ALT elevation group. The effect of inter-
actions between hepatic steatosis and ALT on the risk of lower 
SHBG level was examined by multivariate logistic regression. 
Results are expressed as odds ratios (ORs) with 95% confidence 
intervals (CIs). All analyses were performed using SPSS soft-
ware (version 18.0, SPSS Inc., Chicago, IL, USA). All statistical 
tests were two-sided and significance was determined at a p-
value<0.05. 
RESULTS
Baseline characteristics of each group are described in Table 1. 
In hepatic steatosis with ALT ≥40 group, SHBG was 32.5±13.7, 
which was significantly lower than that of the reference group 
(p<0.001). The subjects in the hepatic steatosis with ALT ≥40 
group had higher BMI, SBP, DBP, glucose, and TG. They were 
more likely to have a history of diabetes. The subjects in the he-
patic steatosis with ALT ≥40 group were also younger and had 
lower HDL cholesterol levels.
Table 2 shows the correlation analysis between SHBG and 
several factors known to be associated with SHBG. BMI, DBP, 
WBC, glucose, cholesterol, and TG were negatively correlated 
with SHBG, while age, T3 and HDL were positively associated 
with SHBG.
Fig. 1 shows the mean values of SHBG for the study popula-
tion between the reference group, hepatic steatosis group with-
out ALT elevation, and hepatic steatosis with ALT elevation 
group after adjustment for several factors. In the hepatic ste-
atosis with ALT elevation group, the mean SHBG level was low-
er than all other groups.
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Multivariate logistic regression models were used to evalu-
ate the relationship between hepatic steatosis and elevated 
ALT levels with the risk of low SHBG levels (Table 3). In multi-
variable regression analysis model 1, adjusting for age and 
BMI, the OR for lower SHBG was 3.287 (95% CI 2.007–5.385) 
in the hepatic steatosis group with ALT ≥40, compared with the 
reference group. Even after progressive adjustment for several 
factors that were previously found to be associated with 
SHBG, the subjects in the hepatic steatosis group with ALT 
≥40 were still more likely to have a lower SHBG level (OR: 
2.729; 95% CI 1.591–4.681). Before we divided men into three 
groups, we conducted a logistic regression analysis to confirm 
if there is an interaction between hepatic steatosis and ALT 
and the risk of lower SHBG level. We found that there was a 
significant interaction between hepatic steatosis and ALT in 
men (p=0.014).
DISCUSSION
In this cross-sectional study, we examined the joint effects of 
hepatic steatosis and ALT on SHBG concentration. A previous 
observational study showed that hepatic steatosis was inde-
pendently related with a low SHBG level.1 In addition , the se-
verity of hepatic steatosis was proportionally correlated with 
the risk of a low SHBG level.2 A previous study also reported 
that serum ALT level was inversely associated with SHBG level.3 
Taken together, hepatic steatosis and serum ALT may be asso-
ciated with a high risk of a low SHBG concentration. However, 
the joint effect of hepatic steatosis and ALT on serum SHBG 
level has not been investigated. In multivariate logistic regres-
sion analysis, we observed that the hepatic metabolic distur-
bance jointly affected low SHBG concentrations independent 
Table 1. Characteristics of the Study Participants
Reference group
(n=388)
Hepatic steatosis with ALT <40 
(n=421)
Hepatic steatosis with ALT ≥40 
(n=113)
p value
Age (yr) 53.5±10.0 55.0±9.6 52.6±9.4 0.007
BMI (kg/m2) 23.4±2.5 25.3±2.8 26.5±2.6 <0.001
SBP (mm Hg) 125.4±15.9 128.4±16.3 130.7±17.5 0.007
DBP (mm Hg) 77.6±9.1 80.3±9.7 81.5±9.8 <0.001
WBC (103/µL) 5.9±1.8 6.3±1.8 6.5±1.7 0.001
Glucose (mg/dL) 97.0±18.9 101.1±16.7 111.0±31.4 <0.001
T3 (ng/mL) 110.2±22.0 110.2±16.7 116.7±29.3 <0.001
Cholesterol (mg/dL) 187.4±33.9 192.6±34.6 193.7±39.2 0.010
HDL (mg/dL) 48.6±10.7 43.6±9.5 42.3±9.7 <0.001
TG* (mg/dL) 93.0 (68.0–124.0) 123.0 (92.0–167.0) 151.0 (99.0–223.0) <0.001
HTN, n (%) 98 (25.3) 137 (32.5) 42 (37.2) 0.013
DM, n (%) 36 (9.3) 56 (13.3) 33 (29.2) <0.001
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; HDL, high density lipoprotein; TG, triglyceride; HTN, 
hypertension; DM, diabetes mellitus; ALT, alanine aminotransferase.
*Data are expressed as the median (25–75%).
Table 2. Correlation between SHBG and Various Parameters
Variables γ p value
Age 0.247 0.000
BMI -0.309 0.000
SBP -0.029 0.368
DBP -0.085 0.009
WBC -0.117 0.000
Glucose -0.090 0.006
T3 0.327 0.000
Cholesterol -0.084 0.010
HDL 0.155 0.000
TG -0.314 0.000
HTN -0.014 0.591
DM -0.052 0.052
SHBG, sex hormone-binding globulin; BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; HDL, high 
density lipoprotein; TG, triglyceride; HTN, hypertension; DM, diabetes mellitus.
Fig. 1. Mean value of SHBG for the study population between reference 
group, hepatic steatosis group with ALT <40, and hepatic steatosis group 
with ALT ≥40. *p<0.01 by multiple co-variant ANOVA controlling for age, 
BMI, SBP, DBP, WBC, glucose, T3, cholesterol, HDL, and TG levels. ALT, 
alanine aminotransferase; SHBG, sex hormone-binding globulin; BMI, body 
mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
WBC, white blood cell; HDL, high density lipoprotein; TG, triglyceride.
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of BMI and metabolic profiles. This is the first report showing 
that increased ALT could be marker of low SHBG in patients 
with hepatic steatosis.
Non-alcoholic fatty liver comprises a spectrum of liver con-
dition ranging from simple steatosis to steatohepatitis and cir-
rhosis. Although liver biopsy is regarded as the gold standard 
for the assessment of the severity of fatty liver, it has limited ap-
plicability in clinical settings, because of the risk related to the 
technique and uncertainty of the distribution of fatty infiltra-
tion. Previous studies have reported an association between 
serum ALT and the grade of hepatic steatosis as confirmed by 
liver biopsy,18 suggesting that patients with fatty liver and higher 
ALT might be at increased risk for a lower SHBG level com-
pared to patients with hepatic steatosis and a lower ALT level. 
Regarding these results, severity of hepatic steatosis may be 
closely associated with lower SHBG levels. Ayala, et al.9 also 
showed that serum SHBG levels were inversely associated with 
ALT serum level. 
Level of SHBG are used in clinical practice to determine 
amounts of free estradiol and testosterone. However, recent 
studies have reported that SHBG levels are altered in several 
diseases, including obesity, thyroid hormone disorder, poly 
cystic ovarian syndrome, and Cushing’s disease.1 In addition, 
several epidemiologic studies have shown that low SHBG levels 
are associated with a higher risk for developing metabolic syn-
drome and type 2 diabetes. Moreover, these relationships are 
dose-dependent and observed even if the SHBG level are with-
in normal range.19,20 Although, the potential roles of SHBG the 
pathogenesis of the metabolic disease remains to be elucidat-
ed, regardless of being within normal range or not, the levels 
of SHBG have clinical meaning.
There are some potential mechanisms by which elevated 
ALT levels affect serum SHBG levels. First, hepatocytes are the 
primary synthesis sites of SHBG, even though SHBG is also 
expressed in testicular germ cells. Thyroid hormone, insulin, 
and cytokines regulate the expression SHBG in hepatocytes.1,21 
These hormones interact with their receptors and activate vari-
ous signal cascades, resulting in alterations of hepatocyte nu-
clear factor 4 alpha protein levels, which regulate SHBG expres-
sion.1 Also, metabolic syndrome, sex hormone, dietary, and liver 
fat influence serum SHBG levels. Hua, et al.22 reported that se-
rum SHBG level was inversely associated with NAFLD and cor-
related with lipid profiles. They observed a negative relation-
ship between serum SHBG and TG and a positive relationship 
between HDL. In a study by Chubb, et al.23 lower SHBG was also 
shown to be associated with increased serum levels of smaller, 
denser low density lipoproteins. The relationship between se-
rum SHBG and lipid profiles was discussed in the study of Des-
meules, et al.24 focusing on post-heparin hepatic lipase and li-
poprotein lipase activity. Previous studies have shown that 
participants with elevated lipoprotein lipase activity had a low-
er TG and higher HDL levels, whereas participants with higher 
hepatic lipase activity had a lower HDL levels. Desmeules, et 
al.24 observed a negative relationship between serum SHBG 
and hepatic lipase activity, where as a positive relationship was 
found between serum SHBG and lipoprotein lipase activity. 
This implied that correlation between lipid profiles and activi-
ty of hepatic lipase and lipoprotein lipase could affect serum 
SHBG levels. In the study by Miksztowicz, et al.25 hepatic li-
pase activity was significantly increased in patients with hepat-
ic steatosis grade 3, compared to those with grade 1. Serum 
SHBG levels were associated with the high-grade NAFLD in 
the study by Shin, et al.7 Correlations of lipid profiles, hepatic 
lipase, lipoprotein lipase, NAFLD, and SHBG were noted with 
NAFLD and elevated liver enzymes. In the study by Ekstedt, et 
al.26 serum ALT levels were elevated in follow-up of NAFLD 
patients with progressive fibrosis. Second, almost all ALT is 
found in the cytosol of hepatocytes. ALT activity in the liver is 
about 3000 times greater than that in the serum. Thus, in cases 
of hepatocellular injury or death, release of ALT from dam-
aged liver cells increases serum ALT levels.27 Therefore, elevat-
ed ALT levels could reflect hepatocellular injury or death, and 
thus could also be associated with a decrease of serum SHBG 
level. Third, insulin resistance could be another possible mecha-
nism explaining this association between ALT and SHBG. Pre-
vious study has suggested that an increased ALT level is asso-
ciated with insulin resistance.22,28 A recent study proposed that 
glucose-induced lipogenesis may affect hepatic production of 
SHBG, and glucose also could directly decrease the expression 
of SHBG.29 In the present study, we observed an inverse rela-
tionship between serum glucose and SHBG concentration. 
Therefore, this finding suggested that there could be interac-
tions among ALT, glucose and SHBG.
Our study has several limitations. First, it followed a retro-
spective cross-sectional method, from which it is difficult to 
conclude a causal relationship. Therefore, a cause-and-effect 
relationship among ALT and SHBG cannot be inferred. Sec-
ond, although a liver biopsy is the gold standard for the diag-
nosis of a hepatic steatosis, a biopsy-proven NAFLD was not 
assessed in the present study. Despite some limitations, ultra-
Table 3. Joint Effects of Hepatic Steatosis and ALT on SHBG in Men
Reference group
Odds ratio (95% CI)
Hepatic steatosis with ALT <40 Hepatic steatosis with ALT ≥40
Model I* 1.00 1.860 (1.297–2.667)‡ 3.287 (2.007–5.385)‡
Model II† 1.00 1.587 (1.083–2.325)‡ 2.729 (1.591–4.681)‡
ALT, alanine aminotransferase; SHBG, sex hormone-binding globulin; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white 
blood cell; HDL, high density lipoprotein; TG, triglyceride; CI, confidence interval.
*Model I: adjusted for age and BMI, †Model II: adjusted for age, BMI, SBP, DBP, WBC, glucose, T3, cholesterol, HDL, and TG levels, ‡p-value<0.01.
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sonography is a non-invasive and preferred modality for mass 
screening for hepatic steatosis with a reasonable sensitivity 
and specificity. Third, our study did not include sex hormone 
levels, which is another factor that influences SHBG synthesis. 
However, despite with these limitations, the present study in-
cludes other meaningful factors, particularly T3 levels which 
could influence SHBG levels. Fourth, exclusion criteria of this 
study did not comprise autoimmune hepatitis. However, in Ko-
rea, the prevalence of autoimmune hepatitis seems to be lower 
than that in Western countries.30 Therefore, the effect of this cri-
terion might be small in this study.
In male patients with hepatic steatosis, elevated serum ALT 
levels were associated with lower serum SHBG levels. Further 
investigation of the association between SHBG and ALT should 
be pursued in future longitudinal studies. 
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